Who are Century Therapeutics, Inc.'s main suppliers?

Century Therapeutics, Inc. (IPSC) key suppliers include: FCDI, Fate Therapeutics, Inc., CytoMed Therapeutics Limited, IN8bio, Inc.. View the full supplier network at chainsifter.com/chain/IPSC.

Who are Century Therapeutics, Inc.'s major customers?

Century Therapeutics, Inc. (IPSC) key customers include: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company, FCDI, Fate Therapeutics, Inc., CytoMed Therapeutics Limited and 2 more. View the full customer network at chainsifter.com/chain/IPSC.

What sector is Century Therapeutics, Inc. in?

Century Therapeutics, Inc. (IPSC) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

IPSC Supply Chain: Century Therapeutics, Inc. Supplier List & 14 Relationships

4Suppliers

7Customers

3Debt Items

20Related Chains

Century Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
FCDI	FCDI	92%	On March 23, 2021, we entered into a Manufacturing and Supply Agreement with FCDI, or, as amended, the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology tran…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE g…
GDTC	CytoMed Therapeutics Limited	72%	Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC g…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellec…

Century Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BMY	Bristol-Myers Squibb Company	90%	the sublicenses under the FCDI Agreements pursuant to our former Research Collaboration and License Agreement with Bristol-Myers Squibb dated January 7, 2022, or the Collaboration Agreement
BMY	Bristol-Myers Squibb Company	90%	Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from BMY grap…
FCDI	FCDI	90%	Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we paid to FCDI (i) an upfront payment of $10.0 million, and will pay (ii) a percentage of any milestone payme…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely…
GDTC	CytoMed Therapeutics Limited	72%	Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n…
INAB	IN8bio, Inc.	72%	Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
TCRX	TScan Therapeutics, Inc.	72%	Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…

Century Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
IPSC-DEBT	Debt stack $43.6M	90%	Market cache reports total debt of $43.6M.
IPSC-DEBT-10343	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.
IPSC-DEBT-10342	Warrants outstanding: 16112	90%	xbrl warrant detail from xbrl 2021-12-31.

Century Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Century Therapeutics, Inc..

Century Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
IPSC-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 75 tracked holders.

Century Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
ACET	Adicet Bio, Inc.	100.00	2
TLSA	Tiziana Life Sciences Ltd	100.00	2
AUTL	Autolus Therapeutics plc	100.00	2
CRSP	CRISPR Therapeutics AG	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
CRBU	Caribou Biosciences, Inc.	100.00	2
DTIL	Precision BioSciences, Inc.	100.00	2
FATE	Fate Therapeutics, Inc.	100.00	2	['customer', 'supplier']
CTMX	CytomX Therapeutics, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ARTV	Artiva Biotherapeutics, Inc.	100.00	1	['spend']

Century Therapeutics, Inc. Supply Chain